B
HLVX

Braidwell’s HilleVax HLVX Stock Holding History

Braidwell’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,064,000
Closed -$1.87M – 83
2024
Q3 		$1.87M Buy
+1,064,000
New +$2.73M 0.05% 78
2024
Q1 		– Sell
-203,407
Closed -$3.26M – 75
2023
Q4 		$3.26M Sell
203,407
-1,245,839
-86% -$16.6M 0.12% 70
2023
Q3 		$19.5M Buy
1,449,246
+200,000
+16% +$2.81M 0.62% 53
2023
Q2 		$21.5M Sell
1,249,246
-370,970
-23% -$5.75M 0.7% 52
2023
Q1 		$26.8M Hold
1,620,216
– – 0.88% 46
2022
Q4 		$27.1M Buy
+1,620,216
New +$29.3M 0.91% 42

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return